Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 12/20 | 0.42 |
| ▸ | STK3 | Q13188 | 1/20 | 0.39 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13724161 | 1.00 | LRRK2 (0.46) | LRRK2FFAR2STK3STK26 | |
| SCHEMBL23623185 | 0.85 | LRRK2 (0.43) | LRRK2FFAR2STK3STK26 | |
| SCHEMBL23623170 | 0.85 | LRRK2 (0.43) | LRRK2FFAR2STK3STK26 | |
| SCHEMBL30205934 | 0.83 | LRRK2 (0.43) | LRRK2FFAR2STK3STK26 | |
| SCHEMBL29173621 | 0.83 | LRRK2 (0.43) | LRRK2FFAR2STK3STK26 | |
| SCHEMBL29209033 | 0.82 | PIK3CA (0.43) | — | |
| SCHEMBL29209035 | 0.82 | PIK3CA (0.43) | — | |
| SCHEMBL29208999 | 0.82 | PIK3CA (0.43) | — | |
| SCHEMBL2144542 | 0.79 | KDM4E (0.46) | LRRK2STK3 | |
| SCHEMBL13724403 | 0.78 | LRRK2 (0.41) | LRRK2FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| WO-2021138434-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | LRRK2 99/4885FFAR2 3521/4885STK3 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.